Aleta’s Novel T Cell Engagers
SugarCone Biotech
MARCH 24, 2025
These agents simultaneously bind to a tumor-associated protein on cancer cells and the CD3 protein on T-cells, facilitating a targeted anti-cancer immune response. When we look at how TCEs interact with targeted cancer cells we can quickly see how cancers respond to T Cell-based therapies. doi: 10.1136/jitc-2021-004348 6.
Let's personalize your content